Immunotherapy – Talk Bio

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

4 days ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

6 days ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

ASCO25 Primer: Navigating Cancer R&D Amid Regulatory Uncertainty

3 weeks ago talkbio0Tagged ASCO25, Cancer Research, Changing, Diagnostics, expert, Immunotherapy, Neoplasms, perspectives, Policy, Precision Medicine, regulatory uncertainty

ASCO25; cancer research; oncology; regulatory uncertainty; immunotherapy; precision medicine; diagnostics; expert perspectives; policy changes

Incyte’s Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection

3 weeks ago talkbio0Tagged Approved, Clinical Trials, Combination Drug Therapy, first-line therapy, Immunotherapy, Incyte, Inhibitor, Malignant neoplasm of anus, PDCD1 gene, POD1UM-303, Retifanlimab, United States Food and Drug Administration, Zynyz

Incyte; Zynyz; retifanlimab; FDA approval; anal cancer; PD-1 inhibitor; first-line therapy; immunotherapy; clinical trial; POD1UM-303; combination chemotherapy

AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data

1 month ago talkbio0Tagged AACR, Cancer Research, Colorectal Carcinoma, Immunotherapy, Malignant neoplasm of breast, Marengo, oncology advancements

Cancer research, AACR 2025, Marengo Therapeutics, BriaCell, oncology advancements, colorectal cancer, breast cancer, immunotherapy

Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval

2 months ago talkbio0Tagged amgen, Biological Factors, DLL3-targeting therapy, Imdelltra, Immunotherapy, Overall Survival, Phase 3 trial, SCLC, small-cell lung cancer

Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals

Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens

4 months ago talkbio0Tagged Cryptigen, CryptoMap platform, DNA, Epitopea, heroin, Immunotherapy, Immunotherapy for cancer, Merck & Co., tumor-specific antigens

Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies

Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

4 months ago talkbio0Tagged Clinical Trials, Failure (biologic function), Immunologic Adjuvants, Immunotherapy, Inhibitor, lymphocyte-activation gene 3 protein, human, melanoma, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

4 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer

4 months ago talkbio0Tagged cell renal cell carcinoma, Conventional (Clear Cell) Renal Cell Carcinoma, Immunotherapy, Malignant neoplasm of kidney, Neoantigen, personalized cancer, phase 1 trial

personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial